Mostafa Kouach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mostafa Kouach has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Jean-François Goossens
Université de Lille, CHU Lille, ULR 7365 – GRITA – Groupe de Recherche sur les formes Injectables et les Technologies Associées Lille France
6 shared publications - Amandine Descat
Centre Universitaire de Mesures et d'Analyses (CUMA), Université de Lille 2, Lille, France
4 shared publications - Bart Staels
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille
3 shared publications - Anne Tailleux
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France
2 shared publications - Catherine Foulon
Univ. Lille, CHU Lille, ULR 7365-GRITA, F-59000 Lille, France
2 shared publications - Damien Lannoy
Univ. Lille, CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France
2 shared publications
Latest Publications
- 8 October 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (4) , e1116-e1123
Maternal Obesity Increases Breast Milk Bile Acid Levels
Context: Breast milk (BM) provides the optimal combination of essential nutrients and bioactive molecules for infant growth and development. However, accumulating evidence from our group and others indicates that maternal factors, such as obesity, can alter BM composition, potentially affecting offspring health outcomes. Bile acids (BA), both primary and secondary, have been identified in human BM but the precise composition and their role in BM remain largely underexplored. Objective: In this study, we analyzed BA profiles in BM and plasma in lactating mothers with obesity or not, across 2 independent clinical cohorts. Methods: BM and plasma samples were collected from breastfeeding women classified as normal weight (N) or with obesity (O). BA concentrations were quantified by reverse phase liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Results: BAs were present in BM, primarily as glyco- and tauro-conjugated of the primary BAs cholic (CA) and chenodeoxycholic acid (CDCA), although at lower levels than in plasma under normal-weight conditions. Maternal obesity led to a marked increase in total BM BA levels while plasma BA concentrations and composition remained unchanged. Additionally, BM BA levels were positively correlated with maternal pre-pregnancy body mass index, circulating leptin (a marker of adiposity), and insulin levels. Conclusion: Our findings identify maternal obesity as a significant modifier of BM BA composition, with potential implications for neonatal digestion, maturation, and health. Further research is warranted to elucidate the impact of these alterations on infant health and development.
- 8 October 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (4) , e1116-e1123
Maternal Obesity Increases Breast Milk Bile Acid Levels
Context: Breast milk (BM) provides the optimal combination of essential nutrients and bioactive molecules for infant growth and development. However, accumulating evidence from our group and others indicates that maternal factors, such as obesity, can alter BM composition, potentially affecting offspring health outcomes. Bile acids (BA), both primary and secondary, have been identified in human BM but the precise composition and their role in BM remain largely underexplored. Objective: In this study, we analyzed BA profiles in BM and plasma in lactating mothers with obesity or not, across 2 independent clinical cohorts. Methods: BM and plasma samples were collected from breastfeeding women classified as normal weight (N) or with obesity (O). BA concentrations were quantified by reverse phase liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Results: BAs were present in BM, primarily as glyco- and tauro-conjugated of the primary BAs cholic (CA) and chenodeoxycholic acid (CDCA), although at lower levels than in plasma under normal-weight conditions. Maternal obesity led to a marked increase in total BM BA levels while plasma BA concentrations and composition remained unchanged. Additionally, BM BA levels were positively correlated with maternal pre-pregnancy body mass index, circulating leptin (a marker of adiposity), and insulin levels. Conclusion: Our findings identify maternal obesity as a significant modifier of BM BA composition, with potential implications for neonatal digestion, maturation, and health. Further research is warranted to elucidate the impact of these alterations on infant health and development.
- Open Access
- 15 August 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (8) , 1071
Impact of Hot-Melt Extrusion on Glibenclamide’s Physical and Chemical States and Dissolution Behavior: Case Studies with Three Polymer Blend Matrices
This research work dives into the complexity of hot-melt extrusion (HME) and its influence on drug stability, focusing on solid dispersions containing 30% of glibenclamide and three 50:50 polymer blends. The polymers used in the study are Ethocel Standard 10 Premium, Kollidon SR and Affinisol HPMC HME 4M. Glibenclamide solid dispersions are characterized using thermal analyses (thermogravimetric analysis (TGA) and differential scanning calorimetry), X-ray diffraction and scanning electron microscopy. This study reveals the transformation of glibenclamide into impurity A during the HME process using mass spectrometry and TGA. Thus, it enables the quantification of the extent of degradation. Furthermore, this work shows how polymer–polymer blend matrices exert an impact on process parameters, the active pharmaceutical ingredient’s physical state, and drug release behavior. In vitro dissolution studies show that the polymeric matrices investigated provide extended drug release (over 24 h), mainly dictated by the polymer’s chemical nature. This paper highlights how glibenclamide is degraded during HME and how polymer selection crucially affects the sustained release dynamics.
- 15 August 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (8) , 1071
Open AccessImpact of Hot-Melt Extrusion on Glibenclamide’s Physical and Chemical States and Dissolution Behavior: Case Studies with Three Polymer Blend Matrices
This research work dives into the complexity of hot-melt extrusion (HME) and its influence on drug stability, focusing on solid dispersions containing 30% of glibenclamide and three 50:50 polymer blends. The polymers used in the study are Ethocel Standard 10 Premium, Kollidon SR and Affinisol HPMC HME 4M. Glibenclamide solid dispersions are characterized using thermal analyses (thermogravimetric analysis (TGA) and differential scanning calorimetry), X-ray diffraction and scanning electron microscopy. This study reveals the transformation of glibenclamide into impurity A during the HME process using mass spectrometry and TGA. Thus, it enables the quantification of the extent of degradation. Furthermore, this work shows how polymer–polymer blend matrices exert an impact on process parameters, the active pharmaceutical ingredient’s physical state, and drug release behavior. In vitro dissolution studies show that the polymeric matrices investigated provide extended drug release (over 24 h), mainly dictated by the polymer’s chemical nature. This paper highlights how glibenclamide is degraded during HME and how polymer selection crucially affects the sustained release dynamics.
- 23 May 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (4) , 898-909
Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis
- 23 May 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (4) , 898-909
Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis
- Open Access
- 4 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1404
Cistracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages: A Stability Study Involving Four Degradation Products
Background: Stability study of a 10 mg/mL injectable cisatracurium solution stored refrigerated in amber glass ampoules for 18 months (M18). Methods: 4000 ampoules were aseptically compounded using European Pharmacopoeia (EP)-grade cisatracurium besylate, sterile water for injection, and benzenesulfonic acid. We developed and validated a stability-indicating HPLC-UV method for cisatracurium and laudanosine. At each stability study time point, we recorded the visual aspect, cisatracurium and laudanosine levels, pH, and osmolality. Sterility, bacterial endotoxin content, and non-visible particles in solution were checked after compounding (T0) and after M12 and M18 of storage. We used HPLC-MS/MS to identify the degradation products (DPs). Results: During the study, osmolality remained stable, pH decreased slightly, and the organoleptic properties did not change. The number of non-visible particles remained below the EP’s threshold. Sterility was preserved, and bacterial endotoxin level remained below the calculated threshold. Cisatracurium concentration remained within the ±10% acceptance interval for 15 months and then decreased to 88.7% of C0 after M18. The laudanosine generated accounted for less than a fifth of the cisatracurium degradation, and three DPs were generated—identified as EP impurity A, impurities E/F, and impurities N/O. Conclusion: Compounded 10 mg/mL cisatracurium injectable solution is stable for at least 15 months.
- 4 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1404
Open AccessCistracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages: A Stability Study Involving Four Degradation Products
Background: Stability study of a 10 mg/mL injectable cisatracurium solution stored refrigerated in amber glass ampoules for 18 months (M18). Methods: 4000 ampoules were aseptically compounded using European Pharmacopoeia (EP)-grade cisatracurium besylate, sterile water for injection, and benzenesulfonic acid. We developed and validated a stability-indicating HPLC-UV method for cisatracurium and laudanosine. At each stability study time point, we recorded the visual aspect, cisatracurium and laudanosine levels, pH, and osmolality. Sterility, bacterial endotoxin content, and non-visible particles in solution were checked after compounding (T0) and after M12 and M18 of storage. We used HPLC-MS/MS to identify the degradation products (DPs). Results: During the study, osmolality remained stable, pH decreased slightly, and the organoleptic properties did not change. The number of non-visible particles remained below the EP’s threshold. Sterility was preserved, and bacterial endotoxin level remained below the calculated threshold. Cisatracurium concentration remained within the ±10% acceptance interval for 15 months and then decreased to 88.7% of C0 after M18. The laudanosine generated accounted for less than a fifth of the cisatracurium degradation, and three DPs were generated—identified as EP impurity A, impurities E/F, and impurities N/O. Conclusion: Compounded 10 mg/mL cisatracurium injectable solution is stable for at least 15 months.
- Open Access
- 9 January 2023
- Published by Wiley in Natural Sciences
- Vol. 3 (2)
Control of lipid metabolism by the dynamic and nutrient‐dependent post‐translational modification O‐GlcNAcylation
O‐GlcNAcylation is a post‐translational modification belonging to the large group of glycosylations. It consists of the modification of cytoplasmic, nuclear, and mitochondrial proteins with a single N‐acetylglucosamine residue by O‐GlcNAc transferase (OGT). Despite its structural simplicity, O‐GlcNAcylation orchestrates many functions inside the cell. This modification regulates fatty acids synthesis, fat storage, and utilization. The generation of white and brown adipocyte‐OGT knock‐out mice has highlighted the marked interference of O‐GlcNAcylation in adiposity and, as a consequence, in metabolic pathologies. OGT is more especially involved in the regulation of lipolysis, and thermogenesis in brown adipose tissue. In addition, O‐GlcNAcylation directly regulates fatty acid synthase, the main enzyme responsible for fatty acids synthesis, and other lipogenic enzymes and transcription factors. Nevertheless, only a few studies reported connections between O‐GlcNAcylation and homeostasis of cholesterol or its derivatives. This knowledge gap is surprising due to the crucial importance of cholesterol in structuring animal biological membranes and as a precursor of a wide variety of biological compounds. Here, we review the current literature about this topic and discuss future prospects in the field.Key points: As a PTM, O‐GlcNAcylation exponentially expands protein functions. O‐GlcNAcylation orchestrates many biological functions in living beings including metabolic fluxes. O‐GlcNAcylation is crucial for fat storage and mobilization, and for fatty acid synthesis but its function in the metabolism of other lipid compounds is less documented.
- 9 January 2023
- Published by Wiley in Natural Sciences
- Vol. 3 (2)
Open AccessControl of lipid metabolism by the dynamic and nutrient‐dependent post‐translational modification O‐GlcNAcylation
O‐GlcNAcylation is a post‐translational modification belonging to the large group of glycosylations. It consists of the modification of cytoplasmic, nuclear, and mitochondrial proteins with a single N‐acetylglucosamine residue by O‐GlcNAc transferase (OGT). Despite its structural simplicity, O‐GlcNAcylation orchestrates many functions inside the cell. This modification regulates fatty acids synthesis, fat storage, and utilization. The generation of white and brown adipocyte‐OGT knock‐out mice has highlighted the marked interference of O‐GlcNAcylation in adiposity and, as a consequence, in metabolic pathologies. OGT is more especially involved in the regulation of lipolysis, and thermogenesis in brown adipose tissue. In addition, O‐GlcNAcylation directly regulates fatty acid synthase, the main enzyme responsible for fatty acids synthesis, and other lipogenic enzymes and transcription factors. Nevertheless, only a few studies reported connections between O‐GlcNAcylation and homeostasis of cholesterol or its derivatives. This knowledge gap is surprising due to the crucial importance of cholesterol in structuring animal biological membranes and as a precursor of a wide variety of biological compounds. Here, we review the current literature about this topic and discuss future prospects in the field.Key points: As a PTM, O‐GlcNAcylation exponentially expands protein functions. O‐GlcNAcylation orchestrates many biological functions in living beings including metabolic fluxes. O‐GlcNAcylation is crucial for fat storage and mobilization, and for fatty acid synthesis but its function in the metabolism of other lipid compounds is less documented.
- Open Access
- 15 July 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , 1287-1302
Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
Background: NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD, in line with highly prevalent dyslipidemia in this population. Increased plasma triglyceride (TG)‐rich lipoprotein (TRL) concentrations, an important risk factor for CVD, are closely linked with hepatic TG content. Therefore, it is of great interest to identify regulatory mechanisms of hepatic TRL production and remnant uptake in the setting of hepatic steatosis. Approach and Results: To identify liver‐regulated pathways linking intrahepatic and plasma TG metabolism, we performed transcriptomic analysis of liver biopsies from two independent cohorts of obese patients. Hepatic encoding apolipoprotein F (APOF) expression showed the fourth‐strongest negatively correlation with hepatic steatosis and the strongest negative correlation with plasma TG levels. The effects of adenoviral‐mediated human ApoF (hApoF) overexpression on plasma and hepatic TG were assessed in C57BL6/J mice. Surprisingly, hApoF overexpression increased both hepatic very low density lipoprotein (VLDL)‐TG secretion and hepatic lipoprotein remnant clearance, associated a ~25% reduction in plasma TG levels. Conversely, reducing endogenous ApoF expression reduced VLDL secretion in vivo, and reduced hepatocyte VLDL uptake by ~15% in vitro. Transcriptomic analysis of APOF‐overexpressing mouse livers revealed a gene signature related to enhanced ApoB‐lipoprotein clearance, including increased expression of Ldlr and Lrp1, among others. Conclusion: These data reveal a previously undescribed role for ApoF in the control of plasma and hepatic lipoprotein metabolism by favoring VLDL‐TG secretion and hepatic lipoprotein remnant particle clearance.
- 15 July 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , 1287-1302
Open AccessApolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
Background: NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD, in line with highly prevalent dyslipidemia in this population. Increased plasma triglyceride (TG)‐rich lipoprotein (TRL) concentrations, an important risk factor for CVD, are closely linked with hepatic TG content. Therefore, it is of great interest to identify regulatory mechanisms of hepatic TRL production and remnant uptake in the setting of hepatic steatosis. Approach and Results: To identify liver‐regulated pathways linking intrahepatic and plasma TG metabolism, we performed transcriptomic analysis of liver biopsies from two independent cohorts of obese patients. Hepatic encoding apolipoprotein F (APOF) expression showed the fourth‐strongest negatively correlation with hepatic steatosis and the strongest negative correlation with plasma TG levels. The effects of adenoviral‐mediated human ApoF (hApoF) overexpression on plasma and hepatic TG were assessed in C57BL6/J mice. Surprisingly, hApoF overexpression increased both hepatic very low density lipoprotein (VLDL)‐TG secretion and hepatic lipoprotein remnant clearance, associated a ~25% reduction in plasma TG levels. Conversely, reducing endogenous ApoF expression reduced VLDL secretion in vivo, and reduced hepatocyte VLDL uptake by ~15% in vitro. Transcriptomic analysis of APOF‐overexpressing mouse livers revealed a gene signature related to enhanced ApoB‐lipoprotein clearance, including increased expression of Ldlr and Lrp1, among others. Conclusion: These data reveal a previously undescribed role for ApoF in the control of plasma and hepatic lipoprotein metabolism by favoring VLDL‐TG secretion and hepatic lipoprotein remnant particle clearance.
- Open Access
Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents
Small molecules targeting the PD-1/PD-L1 checkpoint are actively searched to complement the anticancer arsenal. Different molecular scaffolds have been reported, including phenyl-pyrazolone derivatives which potently inhibit binding of PD-L1 to PD-1. These molecules are structurally close to antioxidant drug edaravone (EDA) used to treat amyotrophic lateral sclerosis. For this reason, we investigated the capacity of five PD-L1-binding phenyl-pyrazolone compounds (1–5) to scavenge the formation of oxygen free radicals using electron spin resonance spectroscopy with DPPH/DMPO probes. In addition, the reactivity of the compounds toward the oxidized base 5-formyluracil (5fU) was assessed using chromatography coupled to mass spectrometry and photodiode array detectors. The data revealed that the phenyl-pyrazolone derivatives display antioxidant properties and exhibit a variable reactivity toward 5fU. Compound 2 with a N-dichlorophenyl-pyrazolone moiety cumulates the three properties, being a potent PD-L1 binder, a robust antioxidant and an aldehyde-reactive compound. On the opposite, the adamantane derivative 5 is a potent PD-L1 binding with a reduced antioxidant potential and no aldehyde reactivity. The nature of the substituent on the phenyl-pyrazolone core modulates the antioxidant capacity and reactivity toward aromatic aldehydes. The molecular signature of the compound can be adapted at will, to confer additional properties to these PD-L1 binders.
Open AccessAntioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents
Small molecules targeting the PD-1/PD-L1 checkpoint are actively searched to complement the anticancer arsenal. Different molecular scaffolds have been reported, including phenyl-pyrazolone derivatives which potently inhibit binding of PD-L1 to PD-1. These molecules are structurally close to antioxidant drug edaravone (EDA) used to treat amyotrophic lateral sclerosis. For this reason, we investigated the capacity of five PD-L1-binding phenyl-pyrazolone compounds (1–5) to scavenge the formation of oxygen free radicals using electron spin resonance spectroscopy with DPPH/DMPO probes. In addition, the reactivity of the compounds toward the oxidized base 5-formyluracil (5fU) was assessed using chromatography coupled to mass spectrometry and photodiode array detectors. The data revealed that the phenyl-pyrazolone derivatives display antioxidant properties and exhibit a variable reactivity toward 5fU. Compound 2 with a N-dichlorophenyl-pyrazolone moiety cumulates the three properties, being a potent PD-L1 binder, a robust antioxidant and an aldehyde-reactive compound. On the opposite, the adamantane derivative 5 is a potent PD-L1 binding with a reduced antioxidant potential and no aldehyde reactivity. The nature of the substituent on the phenyl-pyrazolone core modulates the antioxidant capacity and reactivity toward aromatic aldehydes. The molecular signature of the compound can be adapted at will, to confer additional properties to these PD-L1 binders.
- Open Access
- 18 May 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 1081
Behavior of Regular Insulin in a Parenteral Nutrition Admixture: Validation of an LC/MS-MS Assay and the In Vitro Evaluation of Insulin Glycation
Parenteral-nutrition (PN)-induced hyperglycemia increases morbidity and mortality and must be treated with insulin. Unfortunately, the addition of insulin to a ternary PN admixture leads to a rapid decrease in insulin content. Our study’s objective was to determine the mechanistic basis of insulin’s disappearance. The literature data suggested the presence of a glycation reaction; we therefore validated an LC-MS/MS assay for insulin and glycated insulin. In a 24-h stability study, 20 IU/L of insulin was added to a binary PN admixture at pH 3.6 or 6.3. When the samples were diluted before analysis with a near-neutral diluent, insulin was fully stable at pH 3.6, while a loss of around 50% was observed at pH 6.3. Its disappearance was shown to be inversely correlated with the appearance of monoglycated insulin (probably a Schiff base adduct). Monoglycated insulin might also undergo a back-reaction to form insulin after acidic dilution. Furthermore, a second monoglycated insulin species appeared in the PN admixture after more than 24 h at high temperature (40 °C) and a high insulin concentration (1000 IU/L). It was stable at acidic pH and might be an Amadori product. The impact of insulin glycation under non-forced conditions on insulin’s bioactivity requires further investigation.
- 18 May 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 1081
Open AccessBehavior of Regular Insulin in a Parenteral Nutrition Admixture: Validation of an LC/MS-MS Assay and the In Vitro Evaluation of Insulin Glycation
Parenteral-nutrition (PN)-induced hyperglycemia increases morbidity and mortality and must be treated with insulin. Unfortunately, the addition of insulin to a ternary PN admixture leads to a rapid decrease in insulin content. Our study’s objective was to determine the mechanistic basis of insulin’s disappearance. The literature data suggested the presence of a glycation reaction; we therefore validated an LC-MS/MS assay for insulin and glycated insulin. In a 24-h stability study, 20 IU/L of insulin was added to a binary PN admixture at pH 3.6 or 6.3. When the samples were diluted before analysis with a near-neutral diluent, insulin was fully stable at pH 3.6, while a loss of around 50% was observed at pH 6.3. Its disappearance was shown to be inversely correlated with the appearance of monoglycated insulin (probably a Schiff base adduct). Monoglycated insulin might also undergo a back-reaction to form insulin after acidic dilution. Furthermore, a second monoglycated insulin species appeared in the PN admixture after more than 24 h at high temperature (40 °C) and a high insulin concentration (1000 IU/L). It was stable at acidic pH and might be an Amadori product. The impact of insulin glycation under non-forced conditions on insulin’s bioactivity requires further investigation.
- 13 February 2022
- Published by Wiley in Separation Science Plus
- Vol. 5 (3-4) , 65-74
High‐performance liquid chromatography–ultraviolet detection method to evaluate the migration of di(2‐ethylhexyl) terephthalate and its metabolite from polyvinyl chloride bag in four labile blood products
A liquid chromatography with UV detection method has been developed and validated for the quantitation of di(2‐ethylhexyl)terephthalate, a blood bag plasticizer, and its monoester metabolite, mono(2‐ethylhexyl)terephthalate, in the four labile blood products: whole blood, red cells concentrate, plasma and platelet concentrate. Quantitation thresholds were compared with those obtained using the more conventional tandem mass spectrometry detection and revealed that UV performed better than mass spectrometry for the quantitation of di(2‐ethylhexyl)terephthalate. Liquid‐liquid extraction was selected for sample preparation. Recoveries ranged from 101 to 106 and from 80 to 83%, for di(2‐ethylhexyl)terephthalate and mono(2‐ethylhexyl)terephthalate, respectively, depending on the labile blood product. Repeatability and intermediate precision expressed as relative standard deviation were lower than 20% at the lower limit of quantitation and ranged from 1.9 to 11.2% for the other concentration levels. Regarding the trueness, bias ranged from ‐13.6 to 11.8%. The method was validated considering a total error of ± 20%. Lower limits of quantitation ranged from 500 to 680 nM for di(2‐ethylhexyl)terephthalate and were equal to 500 nM for mono(2‐ethylhexyl)terephthalate. Migration of di(2‐ethylhexyl)terephthalate from polyvinyl chloride blood bags was investigated and mono(2‐ethylhexyl)terephthalate concentrations were determined in each labile blood product.
- 13 February 2022
- Published by Wiley in Separation Science Plus
- Vol. 5 (3-4) , 65-74
High‐performance liquid chromatography–ultraviolet detection method to evaluate the migration of di(2‐ethylhexyl) terephthalate and its metabolite from polyvinyl chloride bag in four labile blood products
A liquid chromatography with UV detection method has been developed and validated for the quantitation of di(2‐ethylhexyl)terephthalate, a blood bag plasticizer, and its monoester metabolite, mono(2‐ethylhexyl)terephthalate, in the four labile blood products: whole blood, red cells concentrate, plasma and platelet concentrate. Quantitation thresholds were compared with those obtained using the more conventional tandem mass spectrometry detection and revealed that UV performed better than mass spectrometry for the quantitation of di(2‐ethylhexyl)terephthalate. Liquid‐liquid extraction was selected for sample preparation. Recoveries ranged from 101 to 106 and from 80 to 83%, for di(2‐ethylhexyl)terephthalate and mono(2‐ethylhexyl)terephthalate, respectively, depending on the labile blood product. Repeatability and intermediate precision expressed as relative standard deviation were lower than 20% at the lower limit of quantitation and ranged from 1.9 to 11.2% for the other concentration levels. Regarding the trueness, bias ranged from ‐13.6 to 11.8%. The method was validated considering a total error of ± 20%. Lower limits of quantitation ranged from 500 to 680 nM for di(2‐ethylhexyl)terephthalate and were equal to 500 nM for mono(2‐ethylhexyl)terephthalate. Migration of di(2‐ethylhexyl)terephthalate from polyvinyl chloride blood bags was investigated and mono(2‐ethylhexyl)terephthalate concentrations were determined in each labile blood product.
- Open Access
Electroseparation of Slaughterhouse By-Product: Antimicrobial Peptide Enrichment by pH Modification
The fractionation of bioactive peptides from hydrolysate is a main challenge to produce efficient alternative for synthetic additives. In this work, electrodialysis with ultrafiltration membrane (EDUF) was proposed to increase the purity of one antimicrobial peptide from slaughterhouse by-product hydrolysate. This targeted-peptide, α137–141 (653 Da, TSKYR), inhibits a large spectrum of microbial growths and delays meat rancidity; therefore, if concentrated, it could be used as food antimicrobial. In this context, three pH values were investigated during EDUF treatment to increase the α137–141 purity: 4.7, 6.5, and 9. pH 9 showed the highest purity increase—75-fold compared to the initial hydrolysate. Although the whole hydrolysate contains more than 100 peptides, only six peptides were recovered at a significant concentration. In this fraction, the α137–141 peptide represented more than 50% of the recovered total peptide concentration. The EDUF α137–141-enriched fraction obtained in this optimized condition would be a promising natural preservative to substitute synthetic additives used to protect food.
Open AccessElectroseparation of Slaughterhouse By-Product: Antimicrobial Peptide Enrichment by pH Modification
The fractionation of bioactive peptides from hydrolysate is a main challenge to produce efficient alternative for synthetic additives. In this work, electrodialysis with ultrafiltration membrane (EDUF) was proposed to increase the purity of one antimicrobial peptide from slaughterhouse by-product hydrolysate. This targeted-peptide, α137–141 (653 Da, TSKYR), inhibits a large spectrum of microbial growths and delays meat rancidity; therefore, if concentrated, it could be used as food antimicrobial. In this context, three pH values were investigated during EDUF treatment to increase the α137–141 purity: 4.7, 6.5, and 9. pH 9 showed the highest purity increase—75-fold compared to the initial hydrolysate. Although the whole hydrolysate contains more than 100 peptides, only six peptides were recovered at a significant concentration. In this fraction, the α137–141 peptide represented more than 50% of the recovered total peptide concentration. The EDUF α137–141-enriched fraction obtained in this optimized condition would be a promising natural preservative to substitute synthetic additives used to protect food.